ADARx Pharmaceuticals has recently completed the full exercise of the underwriters’ option to purchase additional shares that were initially granted in its initial public offering. This closing resulted in the purchase of an additional X shares of the company's common stock. The underwriters opted to purchase these additional shares following the success of the initial public offering.